Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3356087 | 0.83 | ALOX5 (0.36) | HTR2ACYP1A2CYP3A4PPARAABCB11 | |
| SCHEMBL6763475 | 0.79 | CA1 (0.52) | CYP3A4TSHRLMNACYP2A6CA1 | |
| SCHEMBL2782678 | 0.79 | ACHE (0.44) | CYP3A4TSHRLMNAMEN1KMT2A | |
| SCHEMBL7497566 | 0.78 | KDM4E (0.46) | HTR2ALMNASLC6A4KCNH2SLC6A2 | |
| SCHEMBL27870137 | 0.78 | HTR2A (0.43) | HTR2ATSHRMEN1KMT2AMAPT | |
| SCHEMBL7494621 | 0.77 | NFE2L2 (0.42) | CYP1A2TSHRMAOBMAOALMNA | |
| SCHEMBL18419988 | 0.77 | LTA4H (0.47) | HTR2ACYP1A2CYP3A4TSHRLMNA | |
| SCHEMBL98246 | 0.76 | CA4 (0.42) | TSHRLMNA | |
| SCHEMBL7495219 | 0.75 | KMT2A (0.45) | HTR2AMAOBLMNAMEN1KMT2A | |
| SCHEMBL23581950 | 0.74 | CHRNB2 (0.43) | CYP1A2HPGDCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | claimed |
| EP-2173743-A2 | SODIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2010-04-14 | — | — | EP | claimed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | claimed |
| WO-2009012242-A2 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| EP-2922548-A2 | SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL | Stategics, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| US-8871794-B2 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2014081878-A2 | SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL | STATEGICS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140051700-A1 | Small-molecule agonists for type-2 orexin receptor | UNIVERSITY OF TEXAS, BOARD OF REGENTS | 2014-02-20 | — | — | US | disclosed |
| US-8258163-B2 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-09-04 | — | — | US | disclosed |
| CN-102471258-A | 3-phenoxymethylpyrrolidine compounds | THERAVANCE INC | 2012-05-23 | — | — | CN | disclosed |
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100150840-A1 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-17 | — | — | US | disclosed |
| EP-0760368-B1 | PYRIMIDINE DERIVATIVES | NISSHIN FLOUR MILLING CO (JP) | 1999-07-28 | — | — | EP | disclosed |
| US-5753654-A | GASTROINTESTINAL DISORDERS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5736550-A | TREATMENT OF GASTROINTESTINAL TRACT DISORDERS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-04-07 | — | — | US | disclosed |
| EP-0760362-A1 | NOVEL DIAMINOMETHYLIDENE DERIVATIVE | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-03-05 | — | — | EP | disclosed |
| EP-0760368-A1 | NOVEL PYRIMIDINE DERIVATIVE | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-03-05 | — | — | EP | disclosed |
| US-4639447-A | Azolylnitriles, and fungicides containing these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1987-01-27 | — | — | US | disclosed |
| EP-0164088-A2 | Azolyl nitriles and fungicides containing them | BASF Aktiengesellschaft (DE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0129798-A1 | Fungicidal azole compounds, their preparation and use | BASF Aktiengesellschaft (DE) | 1985-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100150840-A1 | Small-molecule agonists for type-2 orexin receptor | HCRTR2, HCRTR1, OXTR | HTR2A 106/4885CYP1A2 647/4885CYP3A4 2188/4885 |
| US-20140051700-A1 | Small-molecule agonists for type-2 orexin receptor | HCRTR2, HCRTR1, OXTR | HTR2A 106/4885CYP1A2 647/4885CYP3A4 2188/4885 |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | HTR2A 1260/4885CYP1A2 2761/4885CYP3A4 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.